Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.53 |
| ▸ | CPA3 | P15088 | 3/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL876930 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL2864873 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL676865 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457950 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9049521 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4457953 | 1.00 | CPA1 (0.53) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6135224 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL305840 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047711 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047718 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7376 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025050066-A1 | COMPOSITIONS INCLUDING SMALL-MOLECULE TERT ACTIVATOR COMPOUNDS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-06 | — | — | WO | claimed |
| CN-119215076-A | Pharmaceutical composition and application thereof | 合肥瀚微生物科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119020862-A | Preparation method of titanium-based oxide mitiglinide phase material | 北京科技大学 | 2024-11-26 | — | — | CN | claimed |
| CN-118787744-A | Pharmaceutical composition and preparation method thereof | 上海宣泰医药科技股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240325362-A1 | NOVEL THERAPEUTIC METHOD FOR ENHANCING MITOCHONDRIAL FUNCTION, TREATING MITOCHONDRIAL DISEASES THEREBY, AND COMPOUNDS USED THEREIN | STANDIGM INC. (KR) | 2024-10-03 | — | — | US | claimed |
| EP-3758692-B1 | COMPOSITIONS AND METHODS FOR TREATING PAIN | UNIV MARYLAND (US) | 2024-08-21 | — | — | EP | claimed |
| CN-114890933-B | Preparation method of racemic mitiglinide | 恒升德康(南京)医药科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117482076-A | Application of methionine compound in preparation of PCSK9 inhibitor | 中国人民解放军陆军军医大学第二附属医院 | 2024-02-02 | — | — | CN | claimed |
| CN-113423404-B | Xanthine derivative pharmaceutical composition and preparation method thereof | 成都苑东生物制药股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002015892-A2 | COMBINATION COMPRISING AN INSULIN SECRETION ENHANCER AND AN ACTIVE INGREDIENT SELECTED FROM HMG-CO-A REDUCTASE INHIBITORS AND ACE INHIBITORS | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| WO-2002015933-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| US-6320058-B2 | SUBJECTING SOLUTION OF PHTHALONITRILE IN TETRAHYDROFURAN, MIXTURE OF TETRAHYDROFURAN AND WATER, OR DIMETHOXYETHANE TO HYDROGEN PRESSURE OF 100 TO 180 BARS, AT TEMPERATURE OF 30 TO 100 DEGREES C., AND IN PRESENCE OF 5% PLATINUM ON CARBON | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | claimed |
| US-20010023294-A1 | New process for the preparation of isoindoline | KISSEI PHARMACEUTICAL COMPANY LTD (JP) | 2001-09-20 | — | — | US | claimed |
| EP-0507534-B1 | Succinic acid compounds | KISSEI PHARMACEUTICAL (JP) | 1996-02-28 | — | — | EP | claimed |